FRAX underestimates fracture risk in patients with diabetes.
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenAssessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directionsDiabetes, bone and glucose-lowering agents: clinical outcomes.Efficacy of Osteoporosis Therapies in Diabetic Patients.Epidemiology of Fractures in Diabetes.Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with and without bone density measures? Data from the Geelong Osteoporosis Study of female cohort.Obesity, Type 2 Diabetes and Bone in Adults.UK clinical guideline for the prevention and treatment of osteoporosisImpaired musculoskeletal response to age and exercise in PPARĪ²(-/-) diabetic miceBone mineralization is elevated and less heterogeneous in adults with type 2 diabetes and osteoarthritis compared to controls with osteoarthritis aloneContemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from ScotlandQuantitative imaging methods in osteoporosis.Fragility fracture: recent developments in risk assessment.Diabetes, diabetic complications, and fracture risk.Predictors of mortality subsequent to a fracture in diabetes mellitus patients.Low Magnesium Exacerbates Osteoporosis in Chronic Kidney Disease Patients with Diabetes.Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies.What Do We Know about Individuals Who Are Assessed as Being at Moderate Risk for Future Fracture in Canada?Determinants of bone strength and quality in diabetes mellitus in humans.Associations with fracture in patients with diabetes: a nested case-control study.High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam StudyDiabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women.The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender DifferencesA review of rodent models of type 2 diabetic skeletal fragility.In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.Evaluation of Singh Index and Osteoporosis Self-Assessment Tool for Asians as risk assessment tools of hip fracture in patients with type 2 diabetes mellitus.BEYOND DXA: ADVANCES IN CLINICAL APPLICATIONS OF NEW BONE IMAGING TECHNOLOGY.Type 2 diabetes and bone.Bone quality: the determinants of bone strength and fragility.Novel assessment tools for osteoporosis diagnosis and treatment.The prevention of fragility fractures in diabetic patients.Complex association between body weight and fracture risk in postmenopausal women.Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors.Osteoporosis in Crisis: It's Time to Focus on Fracture.Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures.DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk?Low-trauma fractures without osteoporosis.Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures.
P2860
Q24612411-6A56A401-6E6E-4D7B-891D-E557FD262FFBQ26750574-F7594E4E-B538-42EC-83C5-89102B9EBDA9Q30234622-AE55B89E-889F-4AD3-AE64-B381A827E701Q30248776-D675B327-3DA0-4D34-AC3A-DBE84FF66221Q30248863-45B0957D-CF6D-4A11-A747-7384853E82CAQ30884007-DD698083-6017-4C59-A090-A8D2117A45EEQ33571597-680934B7-4EE8-4593-A552-B413A21FE6CFQ33581078-691DFD56-ECB2-4BB0-9395-F7648AD5F354Q34551710-1056EF00-83B6-4046-8945-B4FB9A87C426Q34565606-7778290B-FFBA-4DBD-B21A-1C8EC476A879Q34629252-A58FB2AE-9909-4242-9700-4F021FF4E79CQ34680523-BC62EBDF-80E9-4B7A-AE8B-006C422FC90DQ35039567-39048343-E8E4-42AB-930A-9603CA67B0B2Q35156465-BD32D20C-E6F2-4072-8347-DA275936156CQ35239015-CDFB4C50-9D20-47D2-973E-39DEC84D5A5FQ35932324-3AF5C569-68BA-4190-902A-D96F0C855CE9Q36028626-37391DAB-BE80-478A-AE36-A9BB9805C01EQ36217203-40C04E86-CEA3-490B-BB60-6CC7799B8319Q36373016-697290A9-EC97-4B8C-A250-B9502C11D004Q36602825-2CE43821-80F7-4341-93AE-0D657641E97CQ36868093-E3D45879-B90D-4040-B30B-0EB78DC44E49Q36885771-C396A7B4-D2BD-4C91-9BB8-400129744AEAQ37502682-6455AFF7-DD5E-4B86-AD94-AD185E7756A4Q37511845-7FC9E4AE-CDDD-4336-BD9A-735C77B44DADQ37650212-A2596755-1F3F-4FD9-B224-6787EB88C7E2Q37652868-5A4C3468-3752-4FC7-A92A-8225073703FCQ37679196-F53B7895-72E9-4F78-8EDA-6C3BB57B9845Q37744060-A943DF08-12CB-49E7-8063-BB975F291C5EQ38048186-58530A48-5AEA-4B2F-8052-D21CA8974CD6Q38149092-E24E93F6-F13A-441F-B727-8127270C8856Q38216229-957ABA04-4EA9-493F-8C2C-8B3546267A21Q38233593-7232C641-5A25-48CE-9E37-03E779741CCFQ38317545-E977332A-A13F-4ED2-80A6-58C853E8030DQ38441017-7B6DB536-C98D-4314-9AC9-D039488015C1Q38612952-6EF8D7D0-41CA-49AC-B124-FB9BFA1E82F8Q38677489-E534B2CE-B4E7-4387-BE69-1BD35C954580Q38830294-9E5247F8-535A-4F33-AF4E-D33B516A0B4FQ38945656-0F1ECB4C-7EC7-44B6-9F00-1865D56767BFQ38978699-A3BA8F82-493E-4C94-B3B1-98000E567A37Q39060946-3ED693C2-7083-400A-9D48-43EFCDDBC337
P2860
FRAX underestimates fracture risk in patients with diabetes.
description
2012 nĆ® lÅ«n-bĆ»n
@nan
2012幓ć®č«ę
@ja
2012幓č«ę
@yue
2012幓č«ę
@zh-hant
2012幓č«ę
@zh-hk
2012幓č«ę
@zh-mo
2012幓č«ę
@zh-tw
2012幓č®ŗę
@wuu
2012幓č®ŗę
@zh
2012幓č®ŗę
@zh-cn
name
FRAX underestimates fracture risk in patients with diabetes.
@en
FRAX underestimates fracture risk in patients with diabetes.
@nl
type
label
FRAX underestimates fracture risk in patients with diabetes.
@en
FRAX underestimates fracture risk in patients with diabetes.
@nl
prefLabel
FRAX underestimates fracture risk in patients with diabetes.
@en
FRAX underestimates fracture risk in patients with diabetes.
@nl
P2093
P2860
P356
P1476
FRAX underestimates fracture risk in patients with diabetes.
@en
P2093
Anders Oden
Eugene McCloskey
Helena Johansson
John A Kanis
Lisa M Lix
P2860
P304
P356
10.1002/JBMR.556
P577
2012-02-01T00:00:00Z